DOI QR코드

DOI QR Code

A Novel All-trans Retinoid Acid Derivative N-(3-trifluoromethyl-phenyl)-Retinamide Inhibits Lung Adenocarcinoma A549 Cell Migration through Down-regulating Expression of Myosin Light Chain Kinase

  • Fan, Ting-Ting (Department of Respiratory Medicine, the First Affiliated Hospital, Anhui Medical University) ;
  • Cheng, Ying (Department of Respiratory Medicine, the First Affiliated Hospital, Anhui Medical University) ;
  • Wang, Yin-Feng (Department of Respiratory Medicine, the First Affiliated Hospital, Anhui Medical University) ;
  • Gui, Shu-Yu (Department of Respiratory Medicine, the First Affiliated Hospital, Anhui Medical University) ;
  • Chen, Fei-Hu (School of Pharmacy, Anhui Medical University) ;
  • Zhou, Qing (Laboratory of Molecular Biology and Department of Biochemistry, Anhui Medical University) ;
  • Wang, Yuan (Laboratory of Molecular Biology and Department of Biochemistry, Anhui Medical University)
  • Published : 2014.10.11

Abstract

Aim: To observe the effects of a novel all-trans retinoid acid (ATRA) derivative, N-(3-trifluoromethyl-phenyl)-retinamide (ATPR), on lung adenocarcinoma A549 cells and to explore the potential mechanism of ATPR inhibiting of A549 cell migration. Materials and Methods: The cytotoxicity of ATRA and ATPR on A549 cells was assessed using MTT assay. Wound healing assays were used to analyze the influences of ATRA, ATPR, ML-7 (a highly selective inhibitor of myosin light chain kinase (MLCK)), PMA (an activator of MAPKs) and PD98059 (a selective inhibitor of ERK1/2) on the migration of A549 cells. Expression of MLCK and phosphorylation of myosin light chain (MLC) were assessed by Western blotting. Results: ATRA and ATPR inhibited the proliferation of A549 cells in a dose- and time-dependent manner, and the effect of ATPR was much more remarkable compared with ATRA. Relative migration rate and migration distance of A549 cells both decreased significantly after treatment with ATPR or ML-7. The effect on cell migration of PD98059 combining ATPR treatment was more notable than that of ATPR alone. Moreover, compared with control groups, the expression levels of MLCK and phosphorylated MLC in A549 cells were both clearly reduced in ATRA and ATPR groups. Conclusions: ATPR could suppress the migration and invasion of A549 cells, and the mechanism might be concerned with down-regulating the expression of MLCK in the ERK-MAPK signaling pathway, pointing to therapeutic prospects in lung cancer.

Keywords

References

  1. Arafat K, Iratni R, Takahashi T, et al (2013). Inhibitory effects of salinomycin on cell survival, colony growth, migration, and invasion of human non-small cell lung cancer A549 and LNM35: involvement of NAG-1. PLoS One, 8, e66931. https://doi.org/10.1371/journal.pone.0066931
  2. Arisi MF, Starker RA, Addya S, et al (2014). All trans-retinoic acid (ATRA) induces re-differentiation of early transformed breast epithelial cells. Int J Oncol, 44, 1831-42.
  3. Bengtsson AM, Jönsson G, Magnusson C, et al (2013). The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells. BMC Cancer, 13, 336. https://doi.org/10.1186/1471-2407-13-336
  4. Chen C, Diao D, Guo L, et al (2012). All-trans-retinoic acid modulates ICAM-1 N-glycan composition by influencing GnT-III levels and inhibits cell adhesion and transendothelial migration. PLoS One, 7, e52975. https://doi.org/10.1371/journal.pone.0052975
  5. Chen ZX, Tao RF, Xia XM (1992b). The present status in alltrans retinoic acid (ATRA) treatment for acute promyelocytic leukemia patients: further understanding and comprehensive strategy are required in the future. Leuk Lymphoma, 8, 247-52. https://doi.org/10.3109/10428199209051003
  6. Chew TL, Wolf WA, Gallagher PJ, et al (2002). A fluorescent resonant energy transfer based biosensor reveals transient and regional myosin light chain kinase activation in lamella and cleavage furrows. J Cell Biol, 156, 543-53. https://doi.org/10.1083/jcb.200110161
  7. Clemens G, Flower KR, Gardner P, et al (2013). Design and biological evaluation of synthetic retinoids: probing length vs. stability vs. activity. Mol BioSyst, 9, 3124-34. https://doi.org/10.1039/c3mb70273a
  8. D'Antonio C, Passaro A, Gori B, et al (2014). Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol, 6, 101-14. https://doi.org/10.1177/1758834014521110
  9. Dhar AK, Barman PK (2012). Retinoic acid syndrome--cardiac complication. J Assoc Physicians India, 60, 63-5.
  10. Duester G (2008). Retinoic acid synthesis and signaling during early organogenesis. Cell, 134, 921-31. https://doi.org/10.1016/j.cell.2008.09.002
  11. Garattini E, Bolis M, Garattini SK, et al (2014). Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev, 40, 739-49. https://doi.org/10.1016/j.ctrv.2014.01.001
  12. Gui SY, Chen FH, Zhou Q, et al (2011). Effects of novel all-trans retinoic acid retinamide derivatives on the proliferation and apoptosis of human lung adenocarcinoma cell line A549 cells. Yakugaku Zasshi, 131, 1465-72. https://doi.org/10.1248/yakushi.131.1465
  13. Harrison SM, Knifley T, Chen M, et al (2013). LPA, HGF, and EGF utilize distinct combinations of signaling pathways to promote migration and invasion of MDA-MB-231 breast carcinoma cells. BMC Cancer, 13, 501. https://doi.org/10.1186/1471-2407-13-501
  14. Hu KW, Chen FH, Ge JF, et al (2012a). Retinoid receptors in gastric cancer: expression and influence on prognosis. Asian Pac J Cancer Prev, 13, 1809-17. https://doi.org/10.7314/APJCP.2012.13.5.1809
  15. Hu KW, Pan XH, Chen FH, et al (2014b). A novel retinoic acid analog, 4-amino-2- trifluoromethyl-phenyl retinate, inhibits gastric cancer cell growth. Int J Mol Med, 33, 415-22.
  16. Huang ME, Ye YC, Chen SR, et al (1988). Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-72.
  17. Kucharczak J, Pannequin J, Camby I, et al (2001). Gastrin induces over-expression of genes involved in human U373 glioblastoma cell migration. Oncogene, 20, 7021-8. https://doi.org/10.1038/sj.onc.1204882
  18. Lombardi G, Di Stefano AL, Farina P, et al (2014). Systemic treatments for brain metastases from breast cancer, nonsmall cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev, 40, 951-9. https://doi.org/10.1016/j.ctrv.2014.05.007
  19. Mills AM, Beck AH, Montgomery KD, et al (2011). Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry. Am J Surg Pathol, 35, 583-9. https://doi.org/10.1097/PAS.0b013e318211abd6
  20. Munshi PN, Lubin M, Bertino JR (2014). 6-Thioguanine: a drug with unrealized potential for cancer therapy. Oncologist, 19, 760-5. https://doi.org/10.1634/theoncologist.2014-0178
  21. Muralidharan-Chari V, Clancy J, Plou C, et al (2009). ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol, 19, 1875-85. https://doi.org/10.1016/j.cub.2009.09.059
  22. Pan F, Hong LQ (2014). Insulin promotes proliferation and migration of breast cancer cells through the extracellular regulated kinase pathway. Asian Pac J Cancer Prev, 15, 6349-52. https://doi.org/10.7314/APJCP.2014.15.15.6349
  23. Shin DH, Chun YS, Lee KH, et al (2009). Arrest defective-1 controls tumor cell behavior by acetylating myosin light chain kinase. PLoS One, 4, e7451. https://doi.org/10.1371/journal.pone.0007451
  24. Srinivas SP, Satpathy M, Gallagher P, et al (2004). Adenosine induces dephos- phorylation of myosin II regulatory light chain in cultured bovine corneal endothelial cells. Exp Eye Res, 79, 543-51. https://doi.org/10.1016/j.exer.2004.06.027
  25. Sun C, Wu MH, Yuan SY (2011). Nonmuscle myosin light-chain kinase deficiency attenuates atherosclerosis in apolipoprotein E-deficient mice via reduced endothelial barrier dysfunction and monocyte migration. Circulation, 124, 48-57. https://doi.org/10.1161/CIRCULATIONAHA.110.988915
  26. Tang M, Hou YL, Kang QQ, et al (2014). All-trans-retinoic acid promotes iodine uptake via up- regulating the sodium iodide symporter in medullary thyroid cancer stem cells. Asian Pac J Cancer Prev, 15, 1859-62. https://doi.org/10.7314/APJCP.2014.15.4.1859
  27. Wang B, Yan YW, Zhou JL, et al (2013a). A novel all-trans retinoid acid derivatives inhibits the migration of breast cancer cell lines MDA-MB-231 via myosin light chain kinase involving p38-MAPK pathway. Biomed Pharmacother, 67, 357-62. https://doi.org/10.1016/j.biopha.2013.03.016
  28. Wang H, Gui SY, Chen FH, et al (2013b). New insights into 4-Amino-2-tri-fluoromethyl- phenyl ester inhibition of cell growth and migration in the A549 lung adenocarcinoma cell line. Asian Pac J Cancer Prev, 14, 7265-70. https://doi.org/10.7314/APJCP.2013.14.12.7265
  29. Wang N, Ge JF, Pan CX, et al (2013c). Anti-tumor effect of 4-Amino-2-Trifluoromethyl- phenyl retinate on human breast cancer MCF-7 cells via up-regulation of retinoid receptor-induced gene-1. Biomed Pharmacother, 67, 687-92. https://doi.org/10.1016/j.biopha.2013.05.001
  30. Wang XY, Hao JW, Zhou RJ, et al (2013d). Meta-analysis of gene expression data identifies causal genes for prostate cancer. Asian Pac J Cancer Prev, 14, 457-61. https://doi.org/10.7314/APJCP.2013.14.1.457
  31. Wang Z, Sun G, Shen Z, et al (1999e). Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid:10-year experience of its clinical application. Chin Med J (Engl), 112, 963-7.
  32. Zhang ML, Tao Y, Zhou WQ, et al (2014). All-trans retinoic acid induces cell-cycle arrest in human cutaneous squamous carcinoma cells by inhibiting the mitogen activated protein kinase–activated protein 1 pathway. Clin Exp Dermatol, 39, 354-60. https://doi.org/10.1111/ced.12227
  33. Zhang Y, Guan DX, Shi J, et al (2013). All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer. J Hepatol, 59, 1255-63. https://doi.org/10.1016/j.jhep.2013.07.009
  34. Zhou X, Liu Y, You J, et al (2008). Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2. Cancer Lett, 270, 312-27. https://doi.org/10.1016/j.canlet.2008.05.028
  35. Zhuang H, Zhao X, Zhao L, et al (2014). Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. Drug Des Devel Ther, 8, 667-75.
  36. Zhu HQ, Wang F, Dong LY, et al (2014a). MicroRNA1 modulates oxLDL-induced hyperlipidemia by down-regulating MLCK and ERK/p38 MAPK pathway. Life Sci, 107, 21-6. https://doi.org/10.1016/j.lfs.2014.04.028
  37. Zhu P, Chen JM, Guo HM, et al (2012b). Matrine inhibits disturbed flow-enhanced migration via downregulation of ERK1/2-MLCK signaling vascular smooth muscle cells. Ann Vasc Surg, 26, 268-75. https://doi.org/10.1016/j.avsg.2011.10.006
  38. Zimmermann S, Dziadziuszko R, Peters S (2014). Indications and limitations of chemo-therapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev, 40, 716-22. https://doi.org/10.1016/j.ctrv.2014.03.005

Cited by

  1. Melatonin inhibits the Migration of Colon Cancer RKO cells by Down-regulating Myosin Light Chain Kinase Expression through Cross-talk with p38 MAPK vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5835
  2. All-trans retinoic acid inhibits proliferation, migration, invasion and induces differentiation of hepa1-6 cells through reversing EMT in vitro vol.48, pp.1, 2015, https://doi.org/10.3892/ijo.2015.3235